Susceptibilities of human cytomegalovirus clinical isolates and other herpesviruses to new acetylated, tetrahalogenated benzimidazole D-ribonucleosides

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 12, 2009, Pages 5095-5101

  Hwang, Jae Seon ^a   Schilf, Rita ^a   Drach, John C ^b   Townsend, Leroy B ^b   Bogner, Elke ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 BROMO 4,5,6 TRICHLORO 1 (2,3,5 TRI O ACETYL BETA DEXTRO RIBOFURANOSYL) BENZIMIDAZOLE; 2,4,5,6 TETRACHLORO 1 (2,3,5 TRI O ACETYL BETA DEXTRO RIBOFURANOSYL) BENZIMIDAZOLE; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; GANCICLOVIR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DNA REPLICATION; DRUG ACETYLATION; ELECTRON MICROSCOPY; HERPES VIRUS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN CYTOMEGALOVIRUS; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN FIBROBLAST; VARICELLA ZOSTER VIRUS; VIROGENESIS; VIRUS CAPSID;

ANIMALS; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CELL SURVIVAL; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ELECTROPHORESIS, GEL, PULSED-FIELD; HERPES SIMPLEX; HERPES ZOSTER; HERPESVIRUS 1, HUMAN; HERPESVIRUS 3, HUMAN; HUMANS; HYDROCARBONS, HALOGENATED; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; NIH 3T3 CELLS; RATS; RIBONUCLEOSIDES;

EID: 71249105736     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00809-09     Document Type: Article

References (29)

1. Beard, P. M., C. Duffy, and J. D. Baines. 2004. Quantification of the DNA cleavage and packaging proteins UL15 and UL28 in A and B capsids of herpes simplex virus type 1. J. Virol. 78:1367-1374. (Pubitemid 38095846)
2. Biron, K. K. 2006. Antiviral drugs for cytomegalovirus diseases. Antivir. Res. 71:154-163.
3. Biron, K. K., R. J. Harvey, S. C. Chamberlain, S. S. Good, A. A. Smith III, M. G. Davis, C. L. Talarico, W. H. Miller, R. Ferris, R. E. Dornsife, S. C. Stanat, J. C. Drach, L. B. Townsend, and G. W. Koszalka. 2002. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46:2365-2372.
4. Black, L. 1989. DNA packaging in dsDNA bacteriophages. Annu. Rev. Mircrobiol. 43:267-292.
5. Bogner, E. 2002. Human cytomegalovirus terminase as a target for antiviral chemotherapy. Rev. Med. Virol. 12:115-127.
6. Bogner, E., K. Radsak, and M. F. Stinski. 1998. The gene product of human cytomegalovirus open reading frame UL56 binds the pac motif and has specific nuclease activity. J. Virol. 72:2259-2264. (Pubitemid 28100784)
7. Bogner, E., M. Reschke, B. Reis, T. Mockenhaupt, and K. Radsak. 1993. Identification of the gene product encoded by ORF UL56 of the human cytomegalovirus genome. Virology 196:290-293. (Pubitemid 23247216)
8. Britt, W. J., and C. A. Alford. 1996. Cytomegalovirus, p. 2493-2523. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Lippincott- Raven Publishers, Philadelphia, PA.
9. Catalano, C. E. 2000. The terminase enzyme from bacteriophage lambda: a DNA-packaging machine. Cell. Mol. Life Sci. 57:128-148.
10. Casjens, S., and W. M. Huang. 1982. Initiation of sequential packaging of bacteriophage P22 DNA. J. Mol. Biol. 157:287-298.
11. Dittmer, A., J. C. Drach, L. B. Townsend, A. Fischer, and E. Bogner. 2005. Interaction of the putative HCMV portal protein pUL104 with the large terminase subunit pUL56 and its inhibition by benzimidazole-D-ribonucleosides. J. Virol. 79:14660-14667. (Pubitemid 41636264)
12. Drach, J. C., L. B. Townsend, M. R. Nassiri, S. R. Turk, L. A. Coleman, R. V. Devivar, G. Genzlinger, E. D. Kreske, T. E. Renau, A. C. Westerman, C. Shipman, Jr., K. K. Biron, R. Dornsife, and E. R. Kern. 1992. Benzimidazole ribonucleosides: a new class of antivirals with potent and selective activity against human cytomegalovirus. Antivir. Res. 17(Suppl. 1):49.
13. Faulds, D., and R. C. Heel. 1990. Ganciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infection. Drugs 39:597-638.
14. Gelderblom, H. R., E. H. S. Hausmann, M. A. Özel, M. G. Pauli, and M. A. Koch. 1987. Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins. Virology 156:171-176.
15. Hwang, J.-S., and E. Bogner. 2002. ATPase activity of the terminase subunit pUL56 of human cytomegalovirus. J. Biol. Chem. 277:6943-6948.
16. Hwang, J.-S., O. Kregler, R. Schilf, N. Bannert, J. C. Drach, L. B. Townsend, and E. Bogner. 2007. Identification of acetylated, tetrahalogenated benzimidazole D-ribonucleotides with enhanced activity against human cytomegalovirus. J. Virol. 81:11604-11611.
17. Krosky, P. M., M. C. Baek, and D. M. Coen. 2003. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J. Virol. 77:905-914.
18. Krosky, P. M., M. R. Underwood, S. R. Turk, K. W.-H. Feng, R. K. Jain, R. G. Ptak, A. C. Westerman, K. K. Biron, L. B. Townsend, and J. C. Drach. 1998. Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. J. Virol. 72:4721-4728.
19. Mocarski, E. S. 1996. Cytomegaloviruses and their replication, p. 2447-2492. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, PA.
20. Nixon, D. E., and M. A. McVoy. 2004. Dramatic effects of 2-bromo-5,6- dichloro-1-β-D-ribofuranosyl benzimidazole riboside on the genome structure, packaging, and egress of guinea pig cytomegalovirus. J. Virol. 78:1623-1635.
21. Noble, S., and D. Faulds. 1998. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 56:115-146. (Pubitemid 28340192)
22. Reusser, P. 2001. Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts. Expert Opin. Investig. Drugs 10:1745-1753.
23. Scheffczik, H., C. G. W. Savva, A. Holzenburg, L. Kolesnikova, and E. Bogner. 2002. The terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNA-metabolizing proteins with toroidal structure. Nucleic Acids Res. 30:1695-1703. (Pubitemid 34679746)
24. Scholz, B., S. Rechter, J. C. Drach, L. B. Townsend, and E. Bogner. 2003. Identification of the ATP-binding site in the terminase subunit pUL56 of human cytomegalovirus. Nucleic Acids Res. 31:1426-1433. (Pubitemid 36304904)
25. Thoma, C., E. Borst, M. Messerle, M. Rieger, J.-S. Hwang, and E. Bogner. 2006. Identification of the interaction domain of the small terminase subunit pUL89 with the large subunit pUL56 of human cytomegalovirus. Biochemistry 45:8855-8863. (Pubitemid 44100681)
26. Townsend, L. B., R. V. Devivar, S. R. Turk, M. R. Nassiri, and J. C. Drach. 1995. Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(β-Dribofuranosyl) benzimidazoles. J. Med. Chem. 38:4098-4105.
27. Underwood, M. R., R. J. Harvey, S. C. Stanat, M. L. Hemphill, T. Miller, J. C. Drach, L. B. Townsend, and K. K. Biron. 1998. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J. Virol. 72:717-772.
28. Williams, S. L., C. B. Hartline, N. L. Kushner, E. A. Harden, D. J. Bidanset, J. C. Drach, L. B. Townsend, M. R. Underwood, K. K. Biron, and E. R. Kern. 2003. In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob. Agents Chemother. 47:2186-2192.
29. Zacny, V. L., E. Gershburg, M. G. Davis, K. K. Biron, and J. S. Pagano. 1999. Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5,6-dichloro-2-(isopropylamino)-1-beta- L-ribofuranosyl- 1H-benzimidazole. J. Virol. 73:7271-7277.